title: Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin-1.
abstract: BACKGROUND
  In order to assess safety of radioactive iodine administration in the treatment of thyrotoxicosis, we measured concentrations of matrix metalloproteinase-2 (MMP-2), its main inhibitor - TIMP-2 (tissue inhibitor of MMP-2), matrix metalloproteinase-9 (MMP-9), its main inhibitor - TIMP-1, adiponectin, as well as pro-inflammatory and procancerogenic thrombospondin-1 (TSP-1).
  
  
  METHODS
  The study involved 23 patients treated with radioiodine for thyrotoxicosis. Serum concentrations of TSH, free T4, free T3, MMP-2, MMP-9, TIMP-1, TIMP-2, total adiponectin and TSP-1 were measured by immunoassays just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months (visit 3), 6 to 8 months (visit 4) and 15-18 months after radioiodine administration (visit 5).
  
  
  RESULTS
  There were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and TSP-1 (visit 1 vs. 2). Subsequently, there was an increase in MMP-2 (from 393±106 ng/ml to 774±424 ng/ml), TIMP-1 (from 177±76 ng/ml to 296±118 ng/ml), and adiponectin (from 16442±9490 ng/ml to 23518±9840 ng/ml), visit 1 to 5, respectively (p < 0.01). Further analysis revealed no significant change in MMP-2/TIMP-2 ratio, but there was a significant decrease in MMP-9/TIMP-1 ratio (p < 0.05), suggestive of possible decrease in free MMP-9 concentrations.
  
  
  CONCLUSIONS
  Our data reveal a significant and sustained increase in serum adiponectin, as well as possible decrease of free MMP-9 concentration after radioiodine administration. In contrast, there was no significant change of TSP-1. This might indicate overall safety of radioiodine treatment of thyrotoxicosis in terms of the risks of subsequent cardiovascular and neoplastic disease.
authors.affiliation: Department of Endocrinology & Metabolic Diseases, Medical University of Lodz, Polish Mother's Memorial Hospital - Research Institute, Rzgowska 281/289, 93-338 Lodz, Poland. alewin@csk.umed.lodz.pl.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Lewinski
authors.forename: Anna
authors.initials: A
authors.lastname: Brona
authors.forename: Krzysztof C
authors.initials: KC
authors.lastname: Lewandowski
authors.forename: Diana
authors.initials: D
authors.lastname: Jedrzejuk
authors.forename: Anna
authors.initials: A
authors.lastname: Bohdanowicz-Pawlak
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Skowronska-Jozwiak
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Bienkiewicz
authors.forename: Andrzej
authors.initials: A
authors.lastname: Milewicz
references.citation: Trends Cardiovasc Med. 2007 Nov;17(8):253-8
references.pmid: 18021934
references.citation: J Clin Endocrinol Metab. 2007 Mar;92(3):797-800
references.pmid: 17341574
references.citation: J Clin Endocrinol Metab. 2002 Mar;87(3):963-7
references.pmid: 11889143
references.citation: Biochem Pharmacol. 2008 Jan 15;75(2):346-59
references.pmid: 17678629
references.citation: Endocr Rev. 2012 Aug;33(4):547-94
references.pmid: 22547160
references.citation: Int J Biochem Cell Biol. 2006;38(12):2219-28
references.pmid: 16971166
references.citation: Semin Nucl Med. 1978 Jan;8(1):95-103
references.pmid: 76339
references.citation: J Thromb Haemost. 2008 Oct;6(10):1827-30
references.pmid: 18853485
references.citation: Int J Biochem Cell Biol. 2008;40(9):1890-900
references.pmid: 18321763
references.citation: Eur J Intern Med. 2012 Dec;23(8):755-9
references.pmid: 22819464
references.citation: Exp Cell Res. 2005 Mar 10;304(1):187-201
references.pmid: 15707585
references.citation: J R Coll Physicians Lond. 1999 Nov-Dec;33(6):564-7
references.pmid: 10633337
references.citation: Atherosclerosis. 2013 May;228(1):29-35
references.pmid: 23489345
references.citation: Curr Med Chem. 2012;19(8):1193-209
references.pmid: 22257055
references.citation: J Clin Endocrinol Metab. 2007 Jun;92(6):2190-6
references.pmid: 17374710
references.citation: J Clin Endocrinol Metab. 2007 Jun;92(6):2033-5
references.pmid: 17554054
references.citation: Diabetes. 2008 Feb;57(2):432-9
references.pmid: 18057090
references.citation: Med Clin North Am. 2012 Mar;96(2):269-81
references.pmid: 22443975
references.citation: J Pharmacol Sci. 2012;118(1):1-13
references.pmid: 22188858
references.citation: Can J Cardiol. 2007 Jul;23(9):727-33
references.pmid: 17622396
references.citation: Arch Pathol Lab Med. 2008 May;132(5):823-8
references.pmid: 18466032
references.citation: Cancer Res. 2011 Apr 1;71(7):2417-22
references.pmid: 21447745
references.citation: Pak J Biol Sci. 2012 Jan 15;15(2):58-67
references.pmid: 22545358
references.citation: Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83
references.pmid: 10708863
references.citation: Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54
references.pmid: 20498063
references.citation: Thyroid Res. 2012 Oct 29;5(1):12
references.pmid: 23107223
references.citation: J Biol Chem. 1993 Apr 25;268(12):9041-8
references.pmid: 8473345
references.citation: J Clin Endocrinol Metab. 2007 Jul;92(7):2421-9
references.pmid: 17473067
references.citation: Exp Clin Endocrinol Diabetes. 1997;105 Suppl 4:61-5
references.pmid: 9439919
references.citation: JAMA. 2005 Jul 6;294(1):71-80
references.pmid: 15998893
references.citation: Connect Tissue Res. 2008;49(3):257-60
references.pmid: 18661355
references.citation: Curr Opin Pharmacol. 2008 Feb;8(1):82-9
references.pmid: 18226583
references.citation: Hypertension. 2011 Nov;58(5):902-11
references.pmid: 21947471
references.citation: Obes Rev. 2013 Jul;14(7):555-67
references.pmid: 23495931
references.citation: JAMA. 1998 Jul 22-29;280(4):347-55
references.pmid: 9686552
references.citation: Endocrinology. 1999 Mar;140(3):1094-103
references.pmid: 10067831
references.citation: Med Clin North Am. 2012 Mar;96(2):257-68
references.pmid: 22443974